Dec 3, 2020

AI-powered wearable sleep test launches

sleep disorder
sleep apnoea
AI
Leila Hawkins
2 min
AI-powered wearable sleep test launches
Sunrise sits on the wearer's chin and captures movement...

A test that sits on the wearer's chin and uses sensors and AI to detect sleep disorders launches today in the UK. 

Called Sunrise, its creators say it is the world’s first home-based sleep test to provide results equivalent to the polysomnography used in sleep laboratories.  

To use it the wearer places the sensor on the chin before going to sleep. Powered by AI, this records data by measuring the person's chin movements while they're sleeping, based on the premise that jaw movements can indicate sleep apnoea and other disorders. 

The user is then offered the choice to connect with a sleep physician and receive treatment when needed.

The test is the result of a collaboration between the UK's National Heart and Lung Institute and Imperial College London, but is the brainchild of sleep specialist Dr. Jean-Benoit Martinot and over a decade's worth of research. 

A clinical study published in the Journal of the American Medical Association found that Sunrise could be a convenient home-based alternative for sleep studies, to avoid the need to sleep in a hospital bed and be connected to multiple wires.

The test previously launched in France and Belgium, and is now available to buy in the UK where sleep apnoea is estimated to affect 1.5 million adults, although 85 per cent are undiagnosed and therefore untreated.

Martinot, CEO and Co-founder of Sunrise, said: “We are excited to launch into the UK, which is known for its early adoption of innovative and industry leading medtech solutions. Sleep apnoea is a major health issue today with studies having concluded sleep disordered breathing concerns affect 49 per cent of men and 23 per cent of women aged 40 and above². 

"The problem is that the condition remains 80 per cent undiagnosed, and untreated sleep apnoea is linked with serious health problems such as hypertension, heart failure, stroke or diabetes" he added. 

"Additionally, patients suffering from sleep apnoea also appear to be more at risk if they contract COVID-19. As a result of the pandemic, many sleep labs have largely slowed down and we are working with sleep physicians in order to make the steps to getting treatment quick, easy and affordable without compromising the quality of the results.

“Our overarching mission is to help everyone understand that breathing is at the heart of good night’s sleep. We believe sleep should not be a source of anxiety and getting a simple test can bring about more understanding of the quality of sleep.”

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

AI
NHS
skincancer
Cancer
2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article